VALERIE REILLY: Open Payments
NPI 1588655617 · NIPOMO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,519 in 43 payments from 13 companies in 2025. Trend: 2023 $631 · 2024 $1,168 · 2025 $1,519
Food & beverage: $1,519
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $335 |
| ABBVIE INC. | 6 | $224 |
| GlaxoSmithKline, LLC. | 12 | $210 |
| AstraZeneca Pharmaceuticals LP | 2 | $143 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Ascensia Diabetes Care Us Inc. | 2 | $111 |
| Lilly USA, LLC | 3 | $90 |
| PFIZER INC. | 3 | $70 |
| Inspire Medical Systems, Inc. | 1 | $32 |
Products named: Ozempic, VRAYLAR, DUPIXENT, BREZTRI, AREXVY, REZDIFFRA, JARDIANCE, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
